This article is more than 5 years old. Information may no longer be current.

NovaTears+Omega-3 for evaporative dry eye approved in Europe

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NovaTears+Omega-3 has been approved in Europe for the treatment of signs and symptoms of evaporative dry eye disease, according to a Novaliq press release.

The first eye drop to have high concentrations of omega-3 (0.2%) ethyl ester of plant origin, NovaTears+Omega-3 stabilizes the lipid layer of the tear film and reduces evaporation of the underlying water phase of the tear film, supplementing the lipid layer with omega-3 fatty acids, the release said.

“The addition of omega-3 fatty acids to an already powerful NovaTears eye drop will provide dry eye patients with additional relief and physiological benefits by stabilizing the lipid layer,” Jerry Cagle, PhD, a member of Novaliq’s supervisory board, said in the release.